Organon and Braincells to collaborate in discovery and development of CNS drugs

25-Oct-2006 - Netherlands

Organon, the human health care business unit of Akzo Nobel , and BrainCells Inc. (BCI) announced they will collaborate in the discovery and development of drugs for the treatment of central nervous system (CNS) disorders.

BCI will use its proprietary technology in the area of neurogenesis - the process by which pre-existing stem cells in the adult human brain produce new brain tissue, including neurons - to identify neuroscience applications for compounds formerly in the Organon clinical-stage pipeline. When BCI determines the therapeutic utility for a drug candidate, the companies will work together to develop and reposition the drug for its new use.

"We can bring new life to compounds that might otherwise sit on the shelf," said James A. Schoeneck, BCI's CEO. "The collaboration with Organon is a validation of our drug selection technology and development capabilities. By focusing on compounds that have already been tested for safety in the clinic, we can accelerate drug development while minimizing risk."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances